Factors that Predict Clinical Benefit of EGFR TKI Therapy in Patients with <i>EGFR</i> Wild-Type Lung Adenocarcinoma.

Tuberc Respir Dis (Seoul) · 2019 · PMC6304331 · PMID 29926551

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

2.10 months [95% CI, 1.21–2.99], p=0.201) in patients with EGFR wild-type squamous cell carcinoma; however, these associations did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.